Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Macimorelin

            Therapeutic Area: Endocrinology Product Name: Macrilen

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Consilient Health

            Deal Size: Undisclosed Upfront Cash: $1.2 million

            Deal Type: Licensing Agreement December 07, 2020

            Details:

            CH will be responsible for obtaining pricing and reimbursement approval in the European economic area and the U.K, and bearing the regulatory cost for the label extension for pediatric use pending successful outcome of the upcoming study of macimorelin in diagnosis of CGHD

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Insulin

            Therapeutic Area: Endocrinology Product Name: ORMD-0801

            Highest Development Status: Phase III Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 24, 2020

            Details:

            Oramed has screened the first patients in its global Phase 3 trials of its oral insulin capsule ORMD-0801 to treat type 2 diabetes. Both Phase 3 trials, ORA-D-013-1 and ORA-D-013-2, will treat T2D patients who have inadequate glycemic control over a period of 6 to 12 months.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Imeglimin Hydrochloride

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Sumitomo Dainippon Pharma Oncology

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 20, 2020

            Details:

            Metavant has conducted a strategic review and has decided not to move forward with the development of Imeglimin. Metavant will actively explore options for a potential out-licensing of Imeglimin rights for a period of 60 day.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Macimorelin

            Therapeutic Area: Endocrinology Product Name: Macrilen

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Novo Nordisk

            Deal Size: $11.0 million Upfront Cash: $6.1 million

            Deal Type: Licensing Agreement November 16, 2020

            Details:

            Aeterna continues to retain all rights to macimorelin outside of the U.S. and Canada but, in demonstration of Novo Nordisk’s continued commitment to macimorelin, Novo Nordisk has agreed to make an immediate upfront payment to Aeterna of €5 million.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sotagliflozin

            Therapeutic Area: Endocrinology Product Name: Zynquista

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 16, 2020

            Details:

            Sotagliflozin significantly reduced total cardiovascular deaths, heart failure hospitalization and urgent visits, achieving primary endpoint in both studies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tirzepatide

            Therapeutic Area: Endocrinology Product Name: LY3298176

            Highest Development Status: Phase III Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 11, 2020

            Details:

            Eli Lilly and Company will conduct a webcast to provide an overview of the tirzepatide Phase 3 type 2 diabetes clinical trial program in preparation for five future Phase 3 top-line data disclosures.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Teplizumab

            Therapeutic Area: Endocrinology Product Name: PRV-031

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 02, 2020

            Details:

            Teplizumab is an anti-CD3 monoclonal antibody (mAb). The BLA has been submitted for Teplizumab for prevention of clinical type one diabetes (T1D) in at-risk individuals with the submission of the chemistry, manufacturing and controls and administrative information modules.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Testosterone Undecanoate

            Therapeutic Area: Endocrinology Product Name: Tlando

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 14, 2020

            Details:

            Results from the previously completed dose validation ("DV") study of a fixed dose TLANDO in hypogonadal males will also be presented at the meeting.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Teplizumab

            Therapeutic Area: Endocrinology Product Name: PRV-031

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 30, 2020

            Details:

            Teplizumab is an anti-CD3 monoclonal antibody (mAb) being developed for the interception, delay, or prevention of type 1 diabetes (T1D).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Levoketoconazole

            Therapeutic Area: Endocrinology Product Name: Recorlev

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Jefferies

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Public Offering September 16, 2020

            Details:

            The Company intends to use the net proceeds to continue development and regulatory activities, facilitate commercial readiness and commercially launch Recorlev primarily in the US, support the life cycle management activities of Keveyis and for general corporate purposes.